GC
PBYI icon

Grimes & Company’s Puma Biotechnology PBYI Stock Holding History

Grimes & Company’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-16,000
Closed -$135K – 258
2020
Q1 		$135K Sell
16,000
-300
-2% -$2.92K 0.01% 214
2019
Q4 		$143K Buy
16,300
+300
+2% +$2.48K 0.01% 257
2019
Q3 		$172K Buy
+16,000
New +$173K 0.01% 247

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Grimes & Company's PBYI Position: Q2 2020 in Review

Grimes & Company sold out of Puma Biotechnology (PBYI) in Q2 2020, closing a stake of 16,000 shares — an estimated $135K sold.

Grimes & Company first reported a position in PBYI in Q3 2019 and held it in 3 quarters. The position peaked at $172K in Q3 2019. 128 funds tracked by Wall St. Rank hold PBYI as of Q2 2020.

  • Grimes & Company reported no remaining Puma Biotechnology position as of Q2 2020 after selling out during the quarter.
  • Grimes & Company sold 16,000 Puma Biotechnology shares in Q2 2020, an estimated $135K.
  • Grimes & Company first reported a position in Puma Biotechnology in Q3 2019 and held it in 3 quarters.
  • Grimes & Company's Puma Biotechnology position peaked at $172K in Q3 2019.
  • 128 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2020.

Based on Grimes & Company's 13F filing for Q2 2020, filed 31 Jul 2020.